All triptans are not the same

被引：0
作者：
Rapoport A.M. [1 ,2 ]
Tepper S.J. [1 ,2 ]
机构：
[1] New England Center for Headache, Stamford, CT 06902-1251
[2] Department of Neurology, Yale University, School of Medicine, New Haven, CT
来源：
The Journal of Headache and Pain | 2001年 / 2卷 / Suppl 1期
关键词：
5-HT1; agonist; Migraine; Triptan; Vascular headaches;
D O I：
10.1007/s101940170017
中图分类号：
学科分类号：
摘要：
The current review provides a brief summary of the key pre-clinical and clinical characteristics of the triptans that might influence the choice of drug. Data from extensive clinical trials tentatively suggest that eletriptan and rizatriptan may offer an advantage over other triptans on the basis of two clinically important efficacy parameters: eletriptan has the highest likelihood of sustained headache response, while rizatriptan has the highest likelihood of achieving and sustaining a pain-free response. In terms of tolerability, best-in-class goes to naratriptan, almotriptan, and frovatriptan, though the tolerability profile of triptans is very good overall, and patient preference appears to be more closely correlated with efficacy than tolerability. A need is noted for more double-blind studies that directly compare triptans.
引用
收藏
页码：S87 / S92
页数：5
相关论文
共 16 条
  • [1] Schoenen J., Acute migraine therapy: The newer drugs, Curr Opin Neurol, 10, pp. 237-243, (1997)
  • [2] Yu D.K., The contributions of P-glycoprotein to pharmacokinetic drug-drug interactions, J Clin Pharmacol, 39, pp. 1203-1211, (1999)
  • [3] Evans D.C., O'Connor D., Scott-Stevens P., Beer M.S., Tattersall M.J., Hargreaves R.J., Central sites of action are important for the antimigraine efficacy of triptan-5-HT1B/1D agonists, Proceedings of the 9th International Headache Congress, (1999)
  • [4] Wacher V.J., Wu C.Y., Benet L.Z., Overlapping substate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy, Mol Carcinog, 13, pp. 129-134, (1995)
  • [5] Choo E.F., Leake B., Wandel C., Imamura H., Wood A.J.J., Wilkinson G.R., Kim R.B., Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes, Drug Met Dis, 28, pp. 655-660, (2000)
  • [6] Kim R.B., Wandel C., Leake B., Cvetkovic M., Fromm M.F., Dempsey P.J., Roden M.M., Et al., Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein, Pharm Res, 16, pp. 408-414, (1999)
  • [7] Wandel C., Kim R.B., Kayiji S., Ghebreselaise K., Guengerich F.P., Wilkinson G.R., Wood A.J.J., P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies, Cancer Res, 59, pp. 3944-3948, (1999)
  • [8] Tepper S.J., Rapoport A.M., The triptans: A summary, CNS Drugs, 12, pp. 403-417, (1999)
  • [9] Tfelt-Hansen P., De Vries P., Saxena P.R., Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy, Drugs, 60, pp. 1259-1287, (2000)
  • [10] MacIntyre P.D., Bhargava B., Hogg K.J., Gemmill J.D., Hillis W.S., Effect of subcutaneous sumatripan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation, Circulation, 87, pp. 401-405, (1993)
12